Home β€Ί Clinical Evidence Library β€Ί Retinopathy
Ocular

Vision loss from retinopathy is a microvascular problem

Retinopathy β€” whether diabetic, hypertensive, or ischemic β€” results from impaired microvascular supply to the retina. EECP improves retinal blood flow and has shown improvements in visual function.

↑Retinal
Retinal blood flow improves after EECP in diabetic retinopathy
↑VA
Visual acuity improvements observed in clinical case series
↓Leakage
Vascular leakage markers reduce with improved endothelial function
Non-invasive
No injections, no laser β€” purely mechanical vascular treatment
Mechanism of Action

How EECP works for Retinopathy

STEP 01
Diastolic augmentation

Cuffs inflate in diastole, driving a wave of blood retrograde through the aorta β€” increasing coronary perfusion pressure and delivering oxygen-rich blood to ischemic tissue.

STEP 02
Nitric oxide release

Increased shear stress on the endothelium triggers release of nitric oxide β€” the body's master vasodilator β€” improving vessel tone and reducing inflammation.

STEP 03
Angiogenesis

Repeated sessions stimulate VEGF and other growth factors, promoting the formation of new collateral blood vessels in ischemic tissue.

STEP 04
Systemic vascular improvement

Endothelial function improves throughout the body β€” not just at the heart β€” producing benefits in peripheral, cerebral, and microvascular circulation.

Find a provider who treats Retinopathy
Search 139 verified EECP centers β€” filter by condition and location.
Research & Articles

Clinical evidence and patient resources

Click any headline to read the full article. New research and patient stories are added regularly.

Peer-Reviewed Research

Related Studies

5 studies

Peer-reviewed studies, RCTs, and meta-analyses from the EECP clinical evidence library relevant to Diabetic Retinopathy. Click any title to access the source.

RCT
RCT
Consensus
Expert Consensus on Clinical Application of EECP in Elderly People (Lin et al.) β†—

Lin S et al., Chinese Geriatric Branch & Society of Biomedical Engineering Β· Aging Medicine (PMC) Β· 2020

Cohort
EECP for Ocular Ischemic Disease: 86% vs 63% Effectiveness β†—

Yang Z, Wang Y, Zhao J et al. Β· Molecular Medicine Reports Β· 2013

Case
View all research studies in the library β†’
Medical Disclaimer: The information on this page summarizes published clinical research and is provided for educational purposes only. It is not intended as medical advice and should not replace consultation with a qualified healthcare provider. EECP is FDA-cleared for specific cardiac indications; use for other conditions is off-label and should be discussed with your physician.
← Back to Clinical Evidence Library